Globalpharma, a wholly owned subsidiary of Dubai Investments and one of the UAE’s leading pharmaceutical manufacturers, has signed seven strategic Memorandums of Understanding (MoUs) with leading partners to strengthen its capabilities across research and development, manufacturing optimisation, financing and sustainable operations.
The collaborations are structured across three strategic clusters, innovation and product development; manufacturing, efficiency and sustainability; and market access, financing and expansion, designed to deepen Globalpharma’s position across the pharmaceutical value chain.
The Seven Partnerships at a Glance
The MoUs establish collaboration frameworks with partners aligned to each cluster:
Innovation and Product Development
- ZIM Laboratories FZE: Strengthening Globalpharma’s product development pipeline and R&D capabilities for differentiated formulations
- Molkem Chemicals Pvt. Ltd.: Supporting localisation in critical therapeutic areas and improving supply-chain efficiency
Manufacturing, Efficiency and Sustainability
- Masibus (A Sonepar company) & Rockwell Automation: Driving advanced automation and digital technology adoption across Globalpharma’s manufacturing facilities
- 386 Sky Solar Energy Systems LLC: Deploying clean-energy infrastructure across Globalpharma operations
Market Access, Financing and Expansion
- Emirates Development Bank (EDB): Providing structured financing solutions to enable scale and long-term capacity expansion\\
- Mubadala Bio’s Al Ittihad Drug Store (IDS): Strengthening distribution capabilities
- Emirates Drug Establishment (EDE): Supporting pharmaceutical localisation initiatives, regulatory alignment and national medicine security
A National-Priorities Play
Commenting on the signings, Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma, said:
“Strengthening the pharmaceutical sector requires a coordinated approach across innovation, manufacturing and ecosystem development. These MoUs reflect a structured effort to enhance local capabilities, enable technology and knowledge transfer, and support the development of a more resilient and competitive pharmaceutical manufacturing base in the UAE. Through Globalpharma, Dubai Investments continues to support initiatives that align with national priorities while creating long-term value across the healthcare sector.”
From MoU to Measurable Outcome
Dr. Basem Albarahmeh, Chief Executive Officer of Globalpharma, framed the agreements as operational, not symbolic:
“Globalpharma’s focus is on translating these partnerships into tangible operational outcomes. Through our collaboration with ZIM Laboratories, we are strengthening our product development pipeline and building advanced R&D capabilities for differentiated formulations. In parallel, our engagement with Emirates Development Bank supports access to structured financing solutions that enable scale and long-term capacity expansion. These collaborations, alongside our localisation, regulatory and distribution partnerships, strengthen our ability to deliver consistent, high-quality output while supporting long-term operational resilience.”
A 612 kWp Solar Footprint at Dubai Investment Park
The sustainability collaboration with 386 Sky Solar will see the deployment of a 612 kWp rooftop solar photovoltaic (PV) plant at Globalpharma’s Dubai Investment Park facility. The system is expected to:
- Generate approximately 25.3 GWh of clean energy
- Avoid 11,400 tonnes of CO₂ emissions
- Deliver a carbon benefit equivalent to planting over 21,700 trees
Strengthening the Wider Ecosystem
The collaboration with the Emirates Drug Establishment (EDE) supports pharmaceutical localisation initiatives, regulatory alignment, and national medicine security, reinforcing efforts to strengthen local manufacturing capabilities and supply resilience in the UAE.
Globalpharma’s partnerships with Molkem Chemicals and Mubadala Bio’s Al Ittihad Drug Store (IDS) strengthen localisation and distribution capabilities, particularly in critical therapeutic areas, while enhancing supply chain efficiency across the country.
Collectively, the seven MoUs reinforce Globalpharma’s commitment to advancing an integrated pharmaceutical ecosystem and supporting the continued development of the UAE’s healthcare sector.
Source: Globalpharma and Dubai Investments official communications, May 2026. Quotes attributed as cited.
